{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 51 of 122', 'Anaphylaxis is likely when any of the following 3 criteria for suspected anaphylaxis is', 'fulfilled (adapted from Sampson, 2006):', '1. Acute onset of an illness (minutes to hours) with involvement of the skin, mucosal tissue,', 'or both (eg, generalized hives, pruritus or flushing, swollen lips/tongue/uvula) and at least', '1 of the following:', 'Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEFR,', 'hypoxemia)', 'Reduced blood pressure or associated symptoms of end-organ dysfunction', '(eg, hypotonia, syncope, incontinence)', '2. Two or more of the following that occur rapidly after exposure to a likely allergen for the', 'subject (minutes to hours):', 'Involvement of the skin/mucosal tissue (eg, generalized hives, itch/flush, swollen', 'lips/tongue/uvula)', 'Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEFR,', 'hypoxemia)', 'Reduced blood pressure or associated symptoms (eg, hypotonia, syncope,', 'incontinence)', 'Persistent GI symptoms (eg, nausea, crampy abdominal pain, vomiting)', '3. Reduced blood pressure after exposure to a known allergen for the subject (minutes to', 'hours) as follows:', 'Infants and children: > 30% decrease from baseline in systolic blood pressure or low', 'systolic blood pressure in children defined as follows:', '- Age 1 to 10 years: < (70 mm Hg + [2 X age])', '- Age 11 to 17 years: < 90 mm Hg', '8.5.1.2 Assessment of the Tolerability of a Study Product Dose or Dose Level', 'The tolerability of a study product dose or dose level will be assessed based on the', 'occurrence of acute allergy symptoms after dosing. When multiple symptoms are present,', 'the severity of the most severe symptom will be used to determine whether symptoms are', 'dose limiting and the dose or dose level is tolerated. Possible assessments of symptom', 'severity, dose-limiting symptoms, and dose tolerability are shown in Table 12.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 52 of 122', 'Table 12: Allergy Symptom Severity and Study Product Dose Tolerability', 'Symptom Severity', 'Dose-Limiting Symptom', 'Assessed Tolerability of Dose', 'None', 'No', 'Tolerated', 'Mild, oropharyngeal symptoms only', 'No', 'Tolerated', 'Mild, meeting tolerability criteria', 'No', 'Tolerated', 'Mild, not meeting tolerability criteria', 'Yes', 'Not tolerated', 'Moderate, with rare exceptions', 'Yes', 'Not tolerated', 'Severe', 'Yes', 'Not tolerated', 'No Symptoms: A study product dose associated with no allergy symptoms will be assessed', 'as tolerated.', 'Mild symptoms: For a study product dose associated with mild allergy symptoms,', 'investigator assessment is essential in determining if the symptoms are dose limiting. Based', 'on experience with study product, mild symptoms are not dose limiting if they meet all of the', 'tolerability criteria as follows:', 'Are isolated to a single organ system', 'Resolve with no medications or with 2 doses of oral H1 antihistamine', 'Do not require administration of epinephrine', 'Do not worsen in intensity or distribution over time', 'Resolve or show definite signs of resolving in under 1 hour', 'Do not include objective wheezing', 'The study product dose is to be considered not tolerated if mild symptoms do not meet the', 'tolerability criteria as follows:', 'Occur in 2 or more organ systems', 'Require treatment with 3 doses of oral H1 antihistamine or 1 dose of epinephrine', 'Progress in severity or distribution over time', 'Continue longer than expected', 'Include objective wheezing', 'If a study product dose associated with mild symptoms that do not meet the tolerability', 'criteria is assessed as tolerated by the investigator, an explanation must be provided on the', 'case report form.', 'Guidelines for recurrent mild symptoms:', 'GI symptoms were the most common subacute, chronic, and recurrent potential', 'symptoms of allergy in phase 2 and 3 clinical studies of AR101.']\n\n###\n\n", "completion": "END"}